Master the science and clinical applications of GLP-1–based therapies like Ozempic, Wegovy, and Mounjaro
Unlock your potential with a Free coupon code
for the "GLP-1 & GIP Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy" course by Dr. Amogh Gopinathan Nair on Udemy.
This course, boasting a 0.0-star rating from 0 reviews
and with 739 enrolled students, provides comprehensive training in Science.
Spanning approximately
1 hour(s)
, this course is delivered in English
and we updated the information on October 31, 2025.
To get your free access, find the coupon code at the end of this article. Happy learning!
GLP-1 receptor agonists and dual GIP/GLP-1 agonists have transformed the treatment of type 2 diabetes, obesity, and cardiometabolic disorders.
Drugs like Ozempic, Wegovy, and Mounjaro are no longer just glucose-lowering agents; they are reshaping obesity management, cardiovascular risk reduction, and even liver disease therapy.
This course is about GLP-1 & GIP Drugs like Ozempic, Wegovy, and Mounjaro used in Obesity & Diabetes Therapy, and is designed to give you a complete, mechanism-driven understanding of how incretin hormones work, why their biology is so powerful, and how modern therapeutics harness these pathways to benefit the people in need.
You will explore the molecular mechanisms of incretin receptors, pancreatic regulation, and multi-organ effects, and then connect this knowledge to real-world therapeutic applications.
Whether you are in biotech research, pharmacy, medicine, or academia, this course bridges cutting-edge molecular biology with practical pharmacology and clinical insight.
By the end, you’ll be able to:
Explain the physiology of GLP-1 and GIP and their complementary roles in glucose regulation
Understand how receptor signaling differences translate into therapeutic outcomes
Evaluate how incretin therapies impact multiple organs: brain, gut, adipose tissue, and liver
Analyze clinical trial data on HbA1c reduction, weight loss, and cardiovascular protection
Appreciate the evolution from GLP-1 analogues to dual agonists, and where the field is going